After facing a delayed decision deadline and a clinical hold, Regenxbio’s Hunter syndrome gene therapy has been rejected by ...
Eli Lilly is heading back to its regular Chinese collaborator Innovent Biologics with $350 million in upfront cash to ...
Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...
CSL has gotten the Memo about the value of recombinant polyclonal immunoglobulin (IgG) antibodies. | The deal allows CSL to ...
After sharing word that it would be prioritizing artificial intelligence to aid discovery work, Takeda Pharmaceuticals has inked a multiyear deal to access Iambic Therapeutics' broad suite of& | ...
The FDA has flagged J&J Medtech’s recall of its Cerepak detachable coils as Class I in the wake of one death and four serious injuries. | The FDA has flagged J&J Medtech’s recall of Cerepak detachable ...
Bristol Myers Squibb is partnering up with Evinova’s AI clinical development platform across the Big Pharma company’s global portfolio in an effort to improve efficiency and cut costs.
When Expertise, Monitoring, Systems, and AI AlignBy Amir Malka, CEO, Bioforum The Data Masters | Trial oversight is shifting ...
As Eli Lilly awaits an FDA approval decision for its oral GLP-1 orforglipron, the pharma has discarded three clinical-stage ...
AI is no longer a future concept in life sciences — it is actively reshaping how clinical trials are designed, executed and ...
Two dose-limiting toxicities have been recorded in uniQure’s trial evaluating an investigational AAV gene therapy designed to ...
Belgian biotech Agomab Therapeutics and eye-focused drug delivery company SpyGlass Pharma both headed to the Nasdaq this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results